Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | MC4R | P32245 | 1/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
| ▸ | MC3R | P41968 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.48 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.48 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29806269 | 0.83 | KDM4E (0.48) | BAZ2BADORA3TSHRMC4RADRA1A | |
| SCHEMBL640866 | 0.83 | KDM4E (0.48) | BAZ2BADORA3TSHRMC4RADRA1A | |
| SCHEMBL12745729 | 0.78 | KDM4E (0.44) | BAZ2BADORA3TSHRMC4RADRA1A | |
| SCHEMBL1442775 | 0.77 | — | — | |
| Pyrazine Carboxylic Acid Hydrazide SCHEMBL107341 | 0.77 | ADORA3 (0.61) | ADORA3TSHRMC4RADRA1AMC3R | |
| Hydrochloric Acid SCHEMBL3134310 | 0.76 | BAZ2B (0.59) | BAZ2BADORA3TSHRMC4RADRA1A | |
| Hydrochloric Acid SCHEMBL7668906 | 0.76 | BAZ2B (0.59) | BAZ2BADORA3TSHRMC4RADRA1A | |
| Pyrazine Carboxylic Acid Hydrazide SCHEMBL18038330 | 0.75 | ADORA3 (0.59) | ADORA3TSHRMC4RADRA1AMC3R | |
| SCHEMBL14903392 | 0.73 | — | — | |
| SCHEMBL12612179 | 0.73 | ADORA3 (0.46) | ADORA3TSHRMC4RADRA1AMC3R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080096894-A1 | Anti-Bacterial Compounds | ASTON UNIVERSITY (GB) | 2008-04-24 | — | — | US | disclosed |
| EP-1845779-A1 | ANTI-BACTERIAL COMPOUNDS | Aston University (GB) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006075159-A1 | ANTI-BACTERIAL COMPOUNDS | ASTON UNIVERSITY (GB) | 2006-07-20 | — | — | WO | disclosed |
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
| WO-2004110351-A2 | HETEROCYCLIC COMPOUNDS FOR TREATING HEPATITIS C VIRUS | ANADYS PHARMACEUTICALS, INC. (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096894-A1 | Anti-Bacterial Compounds | MRPL21, PGLS, FOSB | BAZ2B 3639/4885ADORA3 4824/4885TSHR 4225/4885 |
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | HAVCR2, HCCS, LIPC | BAZ2B 1262/4885ADORA3 1131/4885TSHR 4398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.